GLP1R and cardiovascular disorder: Additionally, the 2019 guidelines issued by the European Society of Cardiology and the EASD suggest using GLP‐1 RA as initial therapy in patients with type 2 diabetes and cardiovascular disease or those at high risk of cardiovascular disease (no class recommendation).16